Ensysce Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.1M | $5.2M | $2.2M | $2.5M | $3.5M |
| Operating income | -$10.2M | -$6.7M | -$10.7M | -$24.2M | -$19.9M |
| Operating expenses | $15.3M | $11.9M | $12.9M | $26.7M | $23.4M |
| Cash from operations | -$7.8M | -$7.5M | -$10.8M | -$17.9M | -$8.2M |
| Capital expenditure | $123,643 | — | — | — | — |
| Free cash flow | -$7.9M | — | — | — | — |
| Total assets | $7.5M | $5.6M | $2.7M | $5.9M | $16.4M |
| Total liabilities | $4.6M | $2.2M | $3.4M | $9.9M | $24.6M |
Shares outstanding 14.7M · Free float 27.3%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.